Trial By Fire Solutions, LLC Announces Licensing Agreement With Pearl Therapeutics, Inc. for SimpleCTMS
Trial By Fire Solutions announced today that Pearl Therapeuticshas selected SimpleCTMS as their CTMS vendor to optimize the management of their global clinical studies.
The initial Pearl deployment includes multiple Phase II global studies in which SimpleCTMS will be deployed for study startup planning and ongoing study tracking. SimpleCTMS will improve data transparency across service providers, and integrate with other key eClinical systems utilized by Pearl.
The selection of SimpleCTMS by Pearl Therapeutics comes after the successful completion of a CTMS Pilot Program, during which the SimpleCTMS product management and customer support teams were able to quickly and effectively meet and exceed the customer's needs.
SimpleCTMS was designed and developed to offer the benefits of a CTMS (Clinical Trial Management System) without the extensive upfront financial and resource commitments associated with traditional enterprise systems or the inherent inefficiencies of worksheet trackers. Offering flexible subscription pricing, SimpleCTMS provides early stage drug developers a scalable and cost effective solution to improve the management, performance and study startup costs associated with clinical trials.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
